Home » Market News » DirectorsTalk Highlights » Immunotherapy Shots May Reduce Dust Mite Allergy Symptoms
Allergy therapeutics plc

Immunotherapy Shots May Reduce Dust Mite Allergy Symptoms

A British biotechnology company announced the Acarovac Monophosphoryl lipid A (MPL) immunotherapy improved dust mite allergy symptoms during a limited, phase 1 clinical study.

This is important news since around 80 percent of homes in the USA have detectable levels of dust mite allergen.

Acarovac MPL is a subcutaneous immunotherapy product containing Dermatophagoides pteronyssinus and Dermatophagoides farinae allergoids, adsorbed to the adjuvant system comprised of MCT(R) (Microcrystalline Tyrosine) and MPL.

The AM101 study in Spain reported the immunotherapy was well tolerated when administered as 7 injections over 6 to 12 weeks, with each injection scheduled 1 to 2 weeks apart.

Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.